Harbin Pharmaceutical Group Co

Harbin Pharmaceutical Group Co Intangible Assets

The Intangible Assets of Harbin Pharmaceutical Group Co (600664.SS) as of Oct 25, 2026 is 458.51 M CNY. In the previous year, Intangible Assets was 478.24 M CNY — a change of -4.12% (lower).

Intangible Assets

458.51 MCNY

YoY

-4.12%

Last updated:

Intangible Assets of Harbin Pharmaceutical Group Co is 2024 458.51 M CNY. Intangible Assets of Harbin Pharmaceutical Group Co was 2023 478.24 M CNY. It decreases by -4.12% lower compared to the previous year.

The Harbin Pharmaceutical Group Co Intangible Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Intangible Assets
Date
Intangible Assets
Jan 1, 2017
483.00 M CNY
Jan 1, 2018
550.00 M CNY
Jan 1, 2019
528.00 M CNY
Jan 1, 2020
525.00 M CNY
Jan 1, 2021
530.57 M CNY
Jan 1, 2022
491.77 M CNY
Jan 1, 2023
478.24 M CNY
Jan 1, 2024
458.51 M CNY
The Harbin Pharmaceutical Group Co Intangible Assets history
YEARIntangible AssetsYoY
458.51 MCNY-4.12%
478.24 MCNY-2.75%
491.77 MCNY-7.31%
530.57 MCNY+1.06%
525.00 MCNY-0.57%
528.00 MCNY-4.00%
550.00 MCNY+13.87%
483.00 MCNY+11.81%
432.00 MCNY-0.92%
436.00 MCNY-2.46%
447.00 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Harbin Pharmaceutical Group Co Stock analysis

What does Harbin Pharmaceutical Group Co do? Harbin Pharmaceutical Group Co., Ltd. generates revenue by engaging in the research, development, manufacture, wholesale, and retail of pharmaceutical products. The firm focuses on innovative research and development in high-tech fields such as antibiotics, modern Chinese medicine, and biopharmaceuticals. These activities support its main business sectors, which include antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, and pharmaceutical commerce. The company produces a wide range of items, including calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, alprostadil injection, pediatric paracetamol Huangnamin granules, lacidipine tablets, hydrochloric acid for injection Cefotiam, ibuprofen granules, and Xingaizhonggai high calcium tablets. The business is structured around these diverse product lines, serving the needs of the pharmaceutical commerce sector and consumers requiring specific medical treatments. By covering the entire value chain from research and development to retail, the company monetizes its expertise in high-tech fields. The products listed, such as Shuanghuanglian oral solution and amoxicillin capsules, represent the tangible outputs of its manufacturing and wholesale operations, which are central to its financial model. Harbin Pharmaceutical Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Harbin Pharmaceutical Group Co stock

Intangible Assets of Harbin Pharmaceutical Group Co is 458.51 M CNY in 2024.

Intangible Assets of Harbin Pharmaceutical Group Co changed from 478.24 M CNY to 458.51 M CNY, representing a -4.12% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Intangible Assets Harbin Pharmaceutical Group Co since 2006 – with annual values, charts, and detailed analysis.

Intangible assets are non-physical assets such as patents, trademarks, copyrights, and software. They can be significant value drivers for technology and pharmaceutical companies.

Intangible Assets's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Intangible Assets's Harbin Pharmaceutical Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Harbin Pharmaceutical Group Co

All Key Metrics — Harbin Pharmaceutical Group Co